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ABSTRACT
Objectives We conducted a systematic literature review
to assess the adverse event (AE) profile of paracetamol.
Methods We searched Medline and Embase from
database inception to 1 May 2013. We screened for
observational studies in English, which reported
mortality, cardiovascular, gastrointestinal (GI) or renal
AEs in the general adult population at standard
analgesic doses of paracetamol. Study quality was
assessed using Grading of Recommendations
Assessment, Development and Evaluation. Pooled or
adjusted summary statistics were presented for each
outcome.
Results Of 1888 studies retrieved, 8 met inclusion
criteria, and all were cohort studies. Comparing
paracetamol use versus no use, of two studies reporting
mortality one showed a dose–response and reported an
increased relative rate of mortality from 0.95 (0.92 to
0.98) to 1.63 (1.58 to 1.68). Of four studies reporting
cardiovascular AEs, all showed a dose–response with
one reporting an increased risk ratio of all cardiovascular
AEs from 1.19 (0.81 to 1.75) to 1.68 (1.10 to 2.57).
One study reporting GI AEs reported a dose–response
with increased relative rate of GI AEs or bleeds from
1.11 (1.04 to 1.18) to 1.49 (1.34 to 1.66). Of four
studies reporting renal AEs, three reported a dose–
response with one reporting an increasing OR of ≥30%
decrease in estimated glomerular filtration rate from 1.40
(0.79 to 2.48) to 2.19 (1.4 to 3.43).
Discussion Given the observational nature of the data,
channelling bias may have had an important impact.
However, the dose–response seen for most endpoints
suggests a considerable degree of paracetamol toxicity
especially at the upper end of standard analgesic doses.
INTRODUCTION
Paracetamol is the most widely used over-the-
counter and prescription analgesic worldwide.1 It is
the first step on the WHO pain ladder and is cur-
rently recommended as first-line pharmacological
therapy by a variety of international guidelines
for a multitude of acute and chronic painful
conditions.2
The mechanism of paracetamol’s analgesic action
remains largely unknown, but recent studies demon-
strate that paracetamol inhibits prostaglandin pro-
duction within the central nervous system and
within peripheral tissues.3 Irrespective of its efficacy,
it is generally considered to be safer than other
commonly used analgesics such as non-steroidal
anti-inflammatory drugs (NSAIDs) or opiates.
The analgesic benefit of paracetamol has recently
been called into question in the management of
one chronic painful condition, osteoarthritis (OA).4
Clinicians and patients need up-to-date evidence of
benefits and harms to make evidence-based deci-
sions on pharmacological prescription, and a recent
estimate of the true risks of paracetamol at standard
analgesic doses has not been available. We therefore
conducted a systematic review of studies investigat-
ing the association between paracetamol and major
adverse events (AEs) in the general adult popula-
tion to provide a clinically informative toxicity
profile.
METHODS
Data sources and study selection
We followed recommendations made by the Meta-
analysis of Observational Studies in Epidemiology
and the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) groups.5 6
We searched Medline and Embase for English-
language studies published from database inception
to 7 May 2013. The full search strategy was limited
to only identify observational studies and can be
found in the online supplementary material. All
relevant references were checked for additional cita-
tions. Randomised controlled trial (RCT)-level evi-
dence was not considered a meaningful way of
capturing AE data because of the short-term
follow-up of RCT trial participants as well as strict
eligibility for trial entry, meaning that the general
population would not be represented. If cohort-level
evidence was found for an AE outcome, case–
control evidence was not considered.
Studies were eligible for inclusion if they met the
predefined protocol: the study population was
adults aged >18 years and the study investigated
one or more of the AEs of interest when people
were taking oral paracetamol at a standard thera-
peutic dose of 0.5–1 g every 4–6 h to a maximum
of 4 g/day compared with non-use.
Outcomes
The main outcomes investigated were all-cause
mortality, cardiovascular AEs (specifically incidence
of myocardial infarction, cerebrovascular accidents
and hypertension), gastrointestinal (GI) AEs (specif-
ically incidence of GI bleeding) and renal AEs
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(specifically reductions in estimated glomerular filtration rate
(eGFR), increases in serum creatinine concentration and the
need for renal replacement therapy).
We first screened titles and abstracts, and one reviewer (SB)
screened relevant full-text articles. The second reviewer (VDN)
reviewed 10% of the full-text articles screened, which were
selected at random. One reviewer (SB) extracted study character-
istics and adjusted summary statistics with 95% CIs and
recorded the data in a standard form. Two authors (SB and ER)
independently assessed the study quality using Grading of
Recommendations Assessment, Development and Evaluation
(GRADE). Each outcome is given a quality rating of high, mod-
erate, low or very low based upon risk of bias, inconsistency,
indirectness and imprecision. Risk of bias for each outcome was
assessed using checklists for observational studies, which are
based on the Strengthening the Reporting of Observational
Studies in Epidemiology statement.7 GRADE clinical evidence
profiles for each outcome can be found in the online
supplementary material.
Statistical analysis
Studies that met the inclusion criteria and reported summary
statistics with 95% CIs, or presented sufficient data for the cal-
culation of summary statistics and 95% CIs, were considered
for inclusion in meta-analysis. Where data were able to be
pooled, heterogeneity was assessed using the χ2 and I2 statistics.
Heterogeneity was predefined as χ2 p<0.1 or I2 >50%, and
where heterogeneity was unable to be removed by predefined
subgroups a random effects model was assumed and outcomes
were downgraded in quality. In instances where data were
unable to be pooled, due to difference in outcome or paraceta-
mol dosage reporting, individual adjusted summary statistics
were presented for each outcome per study. We produced forest
plots to visually assess the summary statistics and 95% CIs of
each study; analyses were done with Review Manager Version
Five.
RESULTS
The search process identified 1888 records. Eight studies met
the inclusion criteria, all of which were cohort studies. As all
prespecified outcomes were found from these eight cohort
studies, no case–control evidence was considered. Figure 1
shows the PRISMA flow chart for study selection. Table 1
reports the included study characteristics and results. The
quality of evidence varied between outcomes and was graded as
low or very low across all outcomes. Due to the non-comparable
nature of outcomes and different paracetamol dosage definitions
reported by individual studies, meta-analysis was only possible
for a singular outcome; the incidence of hypertension. For all
other outcomes, individual adjusted summary statistics are pre-
sented by AE category.
Two studies reported mortality,8 9 of which one reported a
dose–response increase in the relative rate of all-cause mortality,8
and one reported a significantly increased standardised mortality
ratio for those patients prescribed paracetamol compared with
those not prescribed paracetamol as shown in figure 2.9
Four studies reported cardiovascular AEs,8 10–12 all of which
demonstrated a dose–response. One study reported a dose–
response increase in the risk ratio of cardiovascular AEs (con-
firmed or probable non-fatal myocardial infarction, non-fatal
stroke, fatal coronary heart disease or fatal stroke) as shown in
figure 3;10 one study reported a dose–response increase in the
relative rate of the new cases of myocardial infarction and
stroke;8 and two studies reported a dose–response increase,
which remained when data were pooled, in the relative risk of
new cases of hypertension for those patients taking paracetamol
compared with those not taking paracetamol.11 12
One study reported GI AEs,8 which showed a dose–response
increase in the relative rate of upper GI AEs (gastroduodenal
ulcers and complications such as upper GI haemorrhages) for
those patients prescribed paracetamol compared with those not
prescribed paracetamol as shown in figure 4.
Four studies reported renal AEs,8 13–15 three of which
demonstrated a dose–response. One study reported a dose–
response increase in OR of a decrease of ≥30 mL/min/1.73 m2
in eGFR and ≥30% decrease in eGFR as shown in figure 5;13
one study reported a dose–response increase in the number of
new cases of acute renal failure;8 one study reported a dose–
response increase in OR of ≥0.3 mg/dL increase in serum cre-
atinine and a decrease of ≥30 mL/min/1.73 m2 in eGFR;15 and
one study reported no dose–response relationship in the esti-
mated progression rates of chronic kidney disease and no differ-
ence in time to renal replacement therapy between those taking
paracetamol and those not taking paracetamol.14
DISCUSSION
The objective of this review was to synthesise the long-term
observational evidence of the harmful effects of paracetamol.
Findings from this systematic review demonstrate a consistent
dose–response relationship between paracetamol at standard
analgesic doses and AEs that are often observed with NSAIDs.
This includes a dose–response relationship between paracetamol
and increasing incidence of mortality, cardiovascular, GI and
renal AEs in the general adult population.
The main limitations of this study are the low number of
studies and quality of available evidence. As all studies included
were observational, the GRADE system of quality rating per
outcome begins at ‘low’ quality and can subsequently be
upgraded or downgraded per individual outcome. This initial
‘low’ rating is based purely on the study’s observational designs
and does not take into consideration that observational studies
are the most appropriate study design to assess the risk of long-
term AE outcomes. Five of the studies were conducted in
healthy female registered nurses or male physicians, which may
limit the generalisability of the data to the general popula-
tion.10–13 15
Although the sample size of most included studies was large,
and the reported dosage regimens were consistent with modern
dosage regimens, reliance on self-reported medication use and
channelling bias with incomplete adjustment for potential con-
founders may have had an important impact. Four studies did
not adjust for concomitant NSAID use, and channelling bias
may lead those patients deemed unsuitable for NSAID therapy
to be prescribed paracetamol as a ‘safer’ alternative,8 9 12 14
thus creating an allocation bias to a preselected group of
patients with higher risk of AEs. Often referred to in the litera-
ture as ‘confounding by indication’, the indication and choice of
analgesic treatment by clinicians may be related to the risk of
future health outcomes and result in an imbalance of the under-
lying risk profile between paracetamol and non-paracetamol
groups, potentially leading to biased results. All confounders
adjusted for in each study can be found in the online
supplementary material table S1. Six studies described self-
reported medication use10–15 and two studies8 9 used only para-
cetamol prescription data. Both of these methods have the
potential to inaccurately estimate the true amount of taken para-
cetamol in the studied cohort. A further limitation of the review
is the various definitions of paracetamol dosage regimen across
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studies. Some report lifetime intake, while others report the
number of pills or grams of paracetamol per unit time. This pre-
vented the quantitative pooling of different doses in
meta-analysis and the ability to draw firm conclusions as to safe
dosage regimens.
While these limitations are important to consider, the striking
trend of dose–response is consistent across multiple outcomes
and studies. There is also evidence from the case–control litera-
ture supporting the dose–response seen in the current review,16
and a similar toxicity profile is demonstrated in systematic
reviews of short-term RCTs.4
Several large observational studies confirm a better side effect
profile for paracetamol compared with traditional NSAIDs.17 18
In line with the findings of the current review, one such study
has also shown that the combination use of paracetamol and
NSAIDs significantly increased the number of hospitalisations
for upper GI AEs.18 In keeping with our findings, the addition
of gastroprotective agents to paracetamol prescription signifi-
cantly reduced this event compared with paracetamol alone. As
well, a recent RCT comparing paracetamol and ibuprofen in a
population of patients with knee pain showed 14/192 (7%)
patients in the paracetamol arm experienced a haemoglobin
drop of ≥1 g/dL at day 10, and by week 13 this figure rose to
20%,19 which was not significantly different from the drops in
haemoglobin observed in the ibuprofen-only group.
Every prescribing decision involves a calculation of risk versus
benefit, a trade-off of efficacy versus tolerability. If providing
adequate analgesia or antipyresis, clinicians and patients may be
willing to accept the risk at the level of AEs demonstrated in
this review. However, when analgesic benefit is uncertain, as has
Figure 1 Study selection. *Included animal studies, non-biological science studies and human studies of paracetamol not reporting adverse events.
†Included reviews, editorials and commentaries; types of study not in inclusion criteria; outcome measures other than those in inclusion criteria.
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Table 1 Studies included in the review
Study name
Study
site
Study
design n
Duration of
follow-up
(maximum) (years) Participants
Measure of
effect Outcomes
Exposure
(no-use versus:) Results
Chan et al10 USA Cohort 70 971 12 Female registered nurses
aged 30–55 years
Risk ratio Cardiovascular AEs (confirmed or probable
non-fatal myocardial infarction, non-fatal stroke,
fatal coronary heart disease or fatal stroke)
1–4 days/month use
5–14 days/month use
15–21 days/month use
>22 days/month use
0.98 (0.84 to 1.14)
1.09 (0.91 to 1.30)
1.22 (0.95 to 1.56)
1.35 (1.14 to 1.59)
Curhan et al11 USA Cohort 80 020 2 Female registered nurses
aged 30–55 years
Relative risk Incidence of hypertension 1–4 days/month use
5–14 days/month use
15–21 days/month use
>22 days/month use
1.19 (1.04 to 1.36)
1.37 (1.15 to 1.64)
1.62 (1.22 to 2.16)
2.00 (1.52 to 2.62)
Dedier et al12 USA Cohort 57 935 2 Female registered nurses
aged 30–55 years
Relative risk Incidence of hypertension 1–4 days/month use
5–14 days/month use
15–21 days/month use
>22 days/month use
1.07 (1.02 to 1.13)
1.22 (1.14 to 1.32)
1.31 (1.16 to 1.48)
1.20 (1.08 to 1.33)
Curhan et al13 USA Cohort 1697 11 Female registered nurses
aged 30–55 years
OR Decrease in eGFR of at least 30 mL/min/1.73 m2 100–499 g lifetime intake
500–2999 g lifetime intake
>3000 g lifetime intake
1.80 (1.02 to 3.17)
2.23 (1.36 to 3.63)
2.04 (1.28 to 3.24)
≥ 30% decrease in eGFR 100–499 g lifetime intake
500–2999 g lifetime intake
>3000 g lifetime intake
1.40 (0.79 to 2.49)
1.64 (1.00 to 2.69)
2.19 (1.40 to 3.45)
De Vries et al8 UK Cohort 382 404 20 Patients aged ≥18 received a
prescription for paracetamol
or ibuprofen
Relative rate All-cause mortality First prescription
Long gap (patients with at
least 12 months between
prescriptions)
Low MPR
Medium MPR
High MPR
Very High MPR
1.95 (1.87 to 2.04)
1.18 (1.14 to 1.23)
0.95 (0.92 to 0.97)
1.08 (1.05 to 1.12)
1.27 (1.21 to 1.33)
1.63 (1.58 to 1.68)
Incidence of myocardial infarction First prescription
Long gap (patients with at
least 12 months between
prescriptions)
Low MPR
Medium MPR
High MPR
Very High MPR
1.42 (1.22 to 1.65)
0.98 (0.86 to 1.11)
1.11 (1.02 to 1.19)
1.17 (1.05 to 1.29)
1.04 (0.89 to 1.23)
1.17 (1.04 to 1.32)
Incidence of stroke First prescription
Long gap (patients with at
least 12 months between
prescriptions)
Low MPR
Medium MPR
High MPR
Very High MPR
1.17 (1.02 to 1.35)
1.14 (1.03 to 1.25)
1.03 (0.97 to 1.10)
1.17 (1.08 to 1.27)
1.02 (0.89 to 1.15)
1.30 (1.19 to 1.41)
Upper GI AEs (gastroduodenal ulcers and
complications such as upper GI haemorrhages)
First prescription
Long gap (patients with at
least 12 months between
prescriptions)
Low MPR
Medium MPR
1.74 (1.53 to 1.59)
1.30 (1.17 to 1.46)
1.11 (1.04 to 1.21)
1.25 (1.12 to 1.38)
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Table 1 Continued
Study name
Study
site
Study
design n
Duration of
follow-up
(maximum) (years) Participants
Measure of
effect Outcomes
Exposure
(no-use versus:) Results
High MPR
Very High MPR
1.49 (1.29 to 1.71)
1.49 (1.34 to 1.66)
Incidence of acute renal failure First prescription
Long gap (patients with at
least 12 months between
prescriptions)
Low MPR
Medium MPR
High MPR
Very High MPR
1.31 (1.03 to 1.68)
1.21 (1.02 to 1.43)
1.16 (1.04 to 1.29)
1.27 (1.10 to 1.47)
1.44 (1.18 to 1.75)
1.34 (1.15 to 1.57)
Evans et al14 Sweden Cohort 801 7 People diagnosed with
incident CKD aged ≥18
Regression
coefficient
Differences in estimated progression rates,
(change in eGFR in mL/min/1.73 m2 per year)
<99 g lifetime intake
100–499 g lifetime intake
500–2999 g lifetime intake
>3000 g lifetime intake
−0.17 (−0.9 to 0.6)
0.60 (−0.3 to 1.5)
0.65 (−0.7 to 2.0)
0.24 (−1.2 to 1.7)
HR Time to renal replacement therapy Regular use (at least twice
a week for 2 months prior
to inclusion)
1.1 (0.9 to 1.4)
Kurth et al15 USA Cohort 22 071 14 Healthy male physicians OR Increased creatinine concentration of ≥ 0.3 mg/dL 12–1499 pills/14 years
1500–2499 pills/14 years
>2500 pills/14 years
0.68 (0.48 to 0.98)
0.69 (0.31 to 1.54)
1.11 (0.52 to 2.37)
Decrease in eGFR of at least 30 mL/min/1.73 m2 12–1499 pills/14 years
1500–2499 pills/14 years
>2500 pills/14 years
0.53 (0.36 to 0.78)
0.65 (0.29 to 1.45)
1.28 (0.61 to 2.69)
Lipworth et al9 Denmark Cohort 49 890 7 People prescribed
paracetamol aged over 16
Standardised
mortality ratio
All-cause mortality Prescribed paracetamol
during lifetime
1.9 (1.88 to 1.94)
Renal failure 1.8 (1.3 to 2.5)
Ischemic heart disease 1.6 (1.5 to 1.6)
Other heart disease 1.6 (1.5 to 1.8)
Cerebrovascular disease 1.6 (1.5 to 1.7)
MPR is defined as the ratio of duration of the previous prescription to the time between that prescription and the current prescription. Low MPR = <0.40; medium MPR = 0.40–0.59; high MPR = 0.60–0.79 and very high MPR = >0.8.
AE, adverse event; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; MPR, medication possession ratio.
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Figure 2 Mortality. The relative rate of all-cause mortality in patients taking paracetamol versus patients not taking paracetamol. The
online supplementary material provides the references for the included studies.
Figure 3 Cardiovascular adverse events (AEs). The risk ratio of cardiovascular AEs (confirmed or probable non-fatal myocardial infarction, non-fatal
stroke, fatal coronary heart disease or fatal stroke) in patients taking paracetamol versus patients not taking paracetamol. The online supplementary
material provides the references for the included studies.
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been recently suggested for paracetamol in the treatment of OA
joint pain4 and low back pain, more careful consideration of its
usage is required.20 Prescribers need to be aware of patients’
individual responses to paracetamol and the observed increased
toxicity with regular and higher dosing within standard anal-
gesic dose ranges. Based upon the data presented above, we
believe the true risk of paracetamol prescription to be higher
than that currently perceived in the clinical community. Given
its high usage and availability as an over-the-counter analgesic, a
systematic review of paracetamol’s efficacy and tolerability in
individual conditions is warranted.
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